BACKGROUND AIMS: The Food and Drug Administration (FDA) currently recommends at least 4 h of recipient monitoring after T cell infusions to detect early infusion reactions. Recent catastrophic reactions to 'first-in-man' biologic agents have emphasized the importance of this rule for initial studies of new products. The value of such monitoring for better established agents is less obvious. METHODS: We reviewed infusion-related adverse events (AE) following administration of ex vivo-expanded T cell products (antigen-specific cytotoxic T lymphocytes, allodepleted T cells, and genetically modified T cells) on investigational new drug (IND) studies in our center. RESULTS: From 1998 to 2008, we infused 381 T cell products to 180 recipients, enrolled on 18 studies, receiving T cells targeting malignancies or post-transplant viral infections. There were no grade 3-4 infusion reactions during initial monitoring or 24-h follow-up. Twenty-four mild (grade 1-2) AE occurred in 21 infusions either during or immediately following infusion (up to 6 h), most commonly nausea and vomiting (10/24, 41.6%), probably because of the dimethyl sulfoxide cryoprotectant, and hypotension (20.8%), attributable to diphenhydramine pre-medication. Twenty-two additional non-severe events were reported within 24 h of infusion, most commonly culture-negative fever, chills and nausea. An increased risk of adverse events was associated with age [incidence rate ratio (IRR) 0.98; 95% confidence interval (CI) 0.96-1.00, P = 0.05], while an increased risk of immediate infusion-related events was higher in patients reporting allergies (IRR 2.72, 95% CI 1.00-7.40, P = 0.05); sex, disease type and T cell source (allogeneic or autologous) had no effect on frequency of adverse events. CONCLUSIONS: Infusion of these T cell products was safe in the outpatient setting and associated with no severe reactions, so monitoring for 1 h after infusion is probably sufficient. As many of the AE were attributable to diphenhydramine premedication, a lower dose (0.25 mg/kg) should be selected.
BACKGROUND AIMS: The Food and Drug Administration (FDA) currently recommends at least 4 h of recipient monitoring after T cell infusions to detect early infusion reactions. Recent catastrophic reactions to 'first-in-man' biologic agents have emphasized the importance of this rule for initial studies of new products. The value of such monitoring for better established agents is less obvious. METHODS: We reviewed infusion-related adverse events (AE) following administration of ex vivo-expanded T cell products (antigen-specific cytotoxic T lymphocytes, allodepleted T cells, and genetically modified T cells) on investigational new drug (IND) studies in our center. RESULTS: From 1998 to 2008, we infused 381 T cell products to 180 recipients, enrolled on 18 studies, receiving T cells targeting malignancies or post-transplant viral infections. There were no grade 3-4 infusion reactions during initial monitoring or 24-h follow-up. Twenty-four mild (grade 1-2) AE occurred in 21 infusions either during or immediately following infusion (up to 6 h), most commonly nausea and vomiting (10/24, 41.6%), probably because of the dimethyl sulfoxide cryoprotectant, and hypotension (20.8%), attributable to diphenhydramine pre-medication. Twenty-two additional non-severe events were reported within 24 h of infusion, most commonly culture-negative fever, chills and nausea. An increased risk of adverse events was associated with age [incidence rate ratio (IRR) 0.98; 95% confidence interval (CI) 0.96-1.00, P = 0.05], while an increased risk of immediate infusion-related events was higher in patients reporting allergies (IRR 2.72, 95% CI 1.00-7.40, P = 0.05); sex, disease type and T cell source (allogeneic or autologous) had no effect on frequency of adverse events. CONCLUSIONS: Infusion of these T cell products was safe in the outpatient setting and associated with no severe reactions, so monitoring for 1 h after infusion is probably sufficient. As many of the AE were attributable to diphenhydramine premedication, a lower dose (0.25 mg/kg) should be selected.
Authors: Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley Journal: Nat Rev Cancer Date: 2008-04 Impact factor: 60.716
Authors: Ann M Leen; Anne Christin; Gary D Myers; Hao Liu; Conrad R Cruz; Patrick J Hanley; Alana A Kennedy-Nasser; Kathryn S Leung; Adrian P Gee; Robert A Krance; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Catherine M Bollard Journal: Blood Date: 2009-08-21 Impact factor: 22.113
Authors: Celestia S Higano; Paul F Schellhammer; Eric J Small; Patrick A Burch; John Nemunaitis; Lianng Yuh; Nicole Provost; Mark W Frohlich Journal: Cancer Date: 2009-08-15 Impact factor: 6.860
Authors: Karin C M Straathof; Catherine M Bollard; Uday Popat; M Helen Huls; Teresita Lopez; M Craig Morriss; Mary V Gresik; Adrian P Gee; Heidi V Russell; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop Journal: Blood Date: 2004-11-12 Impact factor: 22.113
Authors: Catherine M Bollard; Laura Aguilar; Karin C Straathof; Benedikt Gahn; M Helen Huls; Alexandra Rousseau; John Sixbey; M Victoria Gresik; George Carrum; Melissa Hudson; Dagmar Dilloo; Adrian Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop Journal: J Exp Med Date: 2004-12-20 Impact factor: 14.307
Authors: Anastasia Papadopoulou; Robert A Krance; Carl E Allen; Daniel Lee; Cliona M Rooney; Malcolm K Brenner; Ann M Leen; Helen E Heslop Journal: Mol Ther Date: 2014-03-21 Impact factor: 11.454
Authors: Patrick J Hanley; Donald R Shaffer; Conrad R Y Cruz; Stephanie Ku; Benjamin Tzou; Hao Liu; Gail Demmler-Harrison; Helen E Heslop; Clio M Rooney; Stephen Gottschalk; Catherine M Bollard Journal: Cytotherapy Date: 2011-05-04 Impact factor: 5.414